Israel-based generics giant Teva Pharmaceutical Industries says that US oncology focussed biotech firm Ignyta has acquired the worldwide rights and assets relating to four targeted oncology development programs in exchange for 1.5 million shares (6%) of Ignyta’s common stock. 18 March 2015
Immunotherapy specialist Celldex Therapeutics has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary effects of varlilumab and APDL3280A together. 18 March 2015
The European Commission has approved Swiss pharma giant Novartis’ Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. 17 March 2015
US biopharma company Pharmacyclics and Johnson & Johnson subsidiary Janssen Biotech have announced that a Phase III trial of Imbruvica (ibrutinib) has been reviewed by an independent monitoring committee. 17 March 2015
Privately-held NantWorks and Sorrento Therapeutics have entered into a second global collaboration, this one to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach. 17 March 2015
Danish drugmaker Genmab has chosen not to exercise the co-development right for HuMax-TAC-ADC under its 2013 agreement with Switzerland-based ADC Therapeutics an oncology drug development company that specializes in the development of proprietary antibody drug conjugates. 16 March 2015
USA-based clinical-stage drug developer Kura Oncology has entered into an agreement with Janssen Pharmaceutica, a subsidiary of health care giant Johnson & Johnson, for an exclusive license to develop and commercialize tipifarnib in the field of oncology. 14 March 2015
US clinical stage biotech firm Epizyme’s) shares rose 14.7% to $25.45 by close of trading on Thursday, after the company revealed that it has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner, Japanese pharma major. 13 March 2015
MultiCell Immunotherapeutics (MCIT), a majority owned subsidiary of MultiCell Technologies, has signed an R&D and product license agreement with Oxis Biotech to create three novel antibody-drug conjugates (ADCs) containing Oxis' lead drug candidates using MCIT's proprietary ADC platform technology. 13 March 2015
US pharma company AbbVie's recent acquisition of Pharmacyclics for $21 billion strengthens AbbVie's already comprehensive pipeline and increases the company's growth prospects, according to Kalorama Information. 13 March 2015
Japan’s largest drugmaker Takeda has transferred its license agreement with the Japan Health Sciences Foundation for worldwide patent rights of a human papillomavirus to the Chemo-Sero-Therapeutic Research Institute (Kaketsuken). 12 March 2015
Shanghai, China-headquartered WuXi PharmaTech announced today that it will soon begin construction of a new, 145,000-square-foot current Good Manufacturing Practices (cGMP) facility in Philadelphia, USA, for the manufacture of cell therapy products. 12 March 2015
Confirming an earlier preliminary guidance, medicines cost watchdog for England, the National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending UK pharma major GlaxoSmithKline’s Arzerra (ofatumumab) with chlorambucil for untreated chronic lymphocytic leukemia (CLL). 11 March 2015
US pharma giant Merck & Co revealed yesterday that its anti-PD-1 therapy, pembrolizumab, which is marketed in the USA under the name Keytruda, is the first treatment to be accepted under the UK’s new Early Access to Medicines Scheme (EAMS). 11 March 2015
Japanese drug major Eisai has announced that its drug Halaven (eribulin) will remain on the UK's National Cancer Drugs Fund in the UK pending reconsideration by the panel. 11 March 2015
Patients in England and Wales with chronic lymphocytic leukemia (CLL) could soon benefit from Gazyvaro (obinutuzumab), after the medicines cost watchdog the National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination (FAD) today recommending the drug for routine use on the National Health Service. 11 March 2015
The US Food and Drug Administration today approved US biotech firm United Therapeutics’ Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a type of cancer that most often occurs in young children. 10 March 2015
US biotech firm CTI BioPharma saw its shares rise 6.4% to $2.82 on Monday, after the company, along with development partner Baxter International, reported positive clinical trial results for their investigational drug pacritinib. 10 March 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024